Loading…

Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin‐based chemotherapy using short hydration: A randomized phase II trial

Background Mannitol is exclusively recommended in the National Comprehensive Cancer Network guidelines for diuresis in cisplatin (CDDP)‐based chemotherapy. The utility of furosemide, a widely used and convenient diuretic, thus requires clarification. Methods This is a prospective, single‐centered, o...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2024-02, Vol.13 (4), p.e6839-n/a
Main Authors: Murakami, Eriko, Akamatsu, Hiroaki, Teraoka, Shunsuke, Takakura, Toshiaki, Takase, Eri, Tanaka, Masanori, Kaki, Takahiro, Harutani, Yuhei, Furuta, Katsuyuki, Sugimoto, Takeya, Shibaki, Ryota, Fujimoto, Daichi, Hayata, Atsushi, Ozawa, Yuichi, Nakanishi, Masanori, Koh, Yasuhiro, Shimokawa, Toshio, Yamamoto, Nobuyuki
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Mannitol is exclusively recommended in the National Comprehensive Cancer Network guidelines for diuresis in cisplatin (CDDP)‐based chemotherapy. The utility of furosemide, a widely used and convenient diuretic, thus requires clarification. Methods This is a prospective, single‐centered, open‐label, noninferiority phase II study. Patients with thoracic malignancies who planned to receive CDDP‐based chemotherapy were randomly assigned to receive either mannitol (arm A) or furosemide (arm B). The primary end point was set as the proportion of patients who experienced any grade of “creatinine (Cr) increased” based on the upper limit of the normal range (ULN) during the first cycle as assessed by Common Terminology Criteria for Adverse Events Version 4.0. Secondary end points were Cr increased based on the baseline value during the first cycle, Cr increased after the completion of CDDP, and the proportion of patients with phlebitis. Results Between April 2018 and March 2022, 115 patients were enrolled and 106 were analyzed. Any grade of Cr increased based on the ULN during the first cycle was 17.3% (arm A) and 24.1% (arm B), respectively (p = 0.34). Therefore, the primary end point was not met. After completion of chemotherapy, any grade of Cr increased was observed in 23.1% (arm A) and 31.5% (arm B), respectively. However, the actual serum Cr level and Cr clearance during the courses were not different between the arms. Phlebitis occurred more frequently in arm A (28.8%) than arm B (16.7%). Conclusions Mannitol should remain the standard diuresis in CDDP‐based chemotherapy assessed by conventional CTCAE grading, but furosemide can be room for consideration when assessed by actual serum Cr level and Cr clearance. This is the largest prospective study to compare furosemide with mannitol in the prevention of renal toxicity in CDDP‐based chemotherapy. The proportion of patients with any grade of creatinine increase during the first cycle was 17.3% in the mannitol arm and 24.1% in the furosemide arm (p = 0.34). Although noninferiority of furosemide to mannitol was unproven, serum creatinine levels and creatinine clearance during the courses were mostly identical.
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.6839